Shire Phase III interim Fosrenol results

Shire (LSE:SHP; SHPGY) reported interim results showing that after one year of a two-year, 1,203-patient U.S. Phase III study to treat hyperphosphatemia in dialysis patients, Fosrenol-treated patients...